Media - 2021 Archive

GENESIS Pharma enters into exclusive agreement with Jazz Pharmaceuticals to commercialize a therapy for certain types of High-Risk Acute Myeloid Leukemia in adults (t-AML and AML-MRC) in Greece, Cyprus and Malta.

29 September 2021 – GENESIS Pharma, a leading regional biopharma company operating in the broader region of South East Europe, announced their exclusive agreement with Jazz Pharmaceuticals, a global biopharmaceutical company dedicated to developing life-changing medicines for serious diseases, for the commercialization of a cancer medicine in Greece, Cyprus and Malta, for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Read More about GENESIS Pharma enters into exclusive agreement with Jazz Pharmaceuticals to commercialize a therapy for certain types of High-Risk Acute Myeloid Leukemia in adults (t-AML and AML-MRC) in Greece, Cyprus and Malta.